Antonella Brunello Selected Research

Neoplasms (Cancer)

5/2022	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy.
1/2022	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
1/2022	Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center.
1/2022	Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.
1/2021	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network.
12/2020	Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations.
10/2020	Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines.
1/2017	Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care).
5/2016	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
1/2016	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonella Brunello Research Topics

Disease

18	Neoplasms (Cancer) 05/2022 - 07/2006
13	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 03/2016
9	Breast Neoplasms (Breast Cancer) 10/2020 - 04/2004
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 01/2009
3	Leiomyosarcoma 01/2022 - 03/2016
2	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2022
2	Infections 01/2022 - 01/2009
2	Epithelioid Hemangioendothelioma 01/2021 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 12/2020 - 07/2014
2	Anemia 10/2020 - 10/2009
2	Fatigue 01/2020 - 03/2016
2	Frailty 07/2017 - 07/2012
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	COVID-19 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Ductal Carcinoma 01/2021
1	Disease Progression 01/2021
1	Menstruation Disturbances 01/2021
1	Neurofibrosarcoma (MPNST) 01/2020
1	Vitelliform Macular Dystrophy 01/2020
1	Aggressive Fibromatosis (Desmoid) 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2020
1	Alopecia (Baldness) 03/2016
1	Liposarcoma 03/2016
1	Vomiting 03/2016
1	Hemangioendothelioma 01/2016
1	Pleural Effusion (Pleural Effusions) 01/2016
1	Wounds and Injuries (Trauma) 09/2014
1	Bone Fractures (Bone Fracture) 07/2012
1	Hyperglycemia 06/2011
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/2011
1	Prostatic Neoplasms (Prostate Cancer) 06/2011
1	Meningitis 01/2011
1	Osteolysis 05/2009
1	Dehydration (Water Stress) 05/2009

Drug/Important Bio-Agent (IBA)

6	AnthracyclinesIBA 12/2021 - 11/2008
5	TrabectedinIBA 01/2022 - 03/2016
4	Ifosfamide FDA LinkGeneric 12/2021 - 01/2007
4	Sunitinib (Sutent)FDA Link 01/2021 - 01/2009
4	Hormones (Hormone)IBA 04/2020 - 01/2008
3	Docetaxel (Taxotere)FDA Link 01/2020 - 11/2008
3	Gemcitabine FDA Link 01/2020 - 11/2008
2	VaccinesIBA 01/2022 - 01/2022
2	Sirolimus (Rapamycin)FDA Link 01/2021 - 01/2016
2	pazopanib FDA Link 01/2021 - 01/2018
2	Tamoxifen FDA LinkGeneric 10/2020 - 04/2020
2	Bleomycin (Blenoxane)FDA LinkGeneric 09/2014 - 04/2014
2	liposomal doxorubicin (Doxil)FDA Link 10/2013 - 11/2008
2	Gefitinib (Iressa)FDA Link 01/2011 - 07/2006
2	Trastuzumab (Herceptin)FDA Link 01/2011 - 11/2008
1	BNT162 VaccineIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2022
1	avapritinibIBA 12/2021
1	ripretinibIBA 12/2021
1	multidrug resistance-associated protein 1IBA 12/2021
1	nilotinib FDA Link 12/2021
1	AZD 6244IBA 12/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Transcriptional Coactivator with PDZ-Binding Motif ProteinsIBA 01/2021
1	IronIBA 10/2020
1	4-hydroxy-N-desmethyltamoxifenIBA 10/2020
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 10/2020
1	HematinicsIBA 10/2020
1	B 43IBA 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 01/2020
1	130-nm albumin-bound paclitaxelIBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 01/2020
1	AlkaloidsIBA 01/2020
1	PeriostinIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	A 17 (A-17)IBA 07/2017
1	Antineoplastic Agents (Antineoplastics)IBA 03/2016
1	1-dodecylpyridoxal (PLD)IBA 10/2013
1	Risedronic Acid (Actonel)FDA LinkGeneric 07/2012
1	Anastrozole (Arimidex)FDA LinkGeneric 07/2012
1	Rituximab (Mabthera)FDA Link 06/2011
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2011
1	Prednisone (Sone)FDA LinkGeneric 06/2011
1	SteroidsIBA 06/2011
1	Vincristine (Oncovin)FDA LinkGeneric 06/2011
1	Sorafenib (BAY 43-9006)FDA Link 01/2011
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2009
1	LigandsIBA 05/2009

Therapy/Procedure

11	Drug Therapy (Chemotherapy) 01/2022 - 07/2006
8	Therapeutics 01/2022 - 01/2008
3	Palliative Care (Palliative Therapy) 05/2022 - 01/2017
2	Ambulatory Care (Outpatient Care) 05/2022 - 05/2016
2	Radiotherapy 01/2022 - 03/2016
2	Neoadjuvant Therapy 01/2022 - 01/2020
1	Aftercare (After-Treatment) 01/2022
1	Adjuvant Radiotherapy 01/2021
1	Precision Medicine 01/2017
1	Adjuvant Chemotherapy 03/2016
1	Debridement 09/2014
1	Polypharmacy 07/2014
1	Electrodes (Electrode) 04/2014
1	Glycemic Control 06/2011